Bladder Cancer
ASCO GU 2019: Updates on Treatment and Management of Bladder Cancer
Latest in Urology
Immunotherapy Reseach
Super-Responders vs. Hyper-Progression with Immunotherapy
The trial revealed a linear correlation between higher tumor burden and anti-PD1 and anti-programmed death ligand (PD-L1) checkpoint inhibitors, explained as the immune system responding to reactivation.
Mar 10, 2017
| Bladder Cancer Content Hub, Hematology-Oncology, Internal Medicine, Men's Health, Urology, Women’s Health
Multiple clinical trials are currently underway examining the possible synergistic effects of combining chemotherapy with immunotherapies for patients with bladder cancer and other...
Prostate Exam Practice Progresses
Jul 8, 2016
